Journal article
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
- Abstract:
-
Background: Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdO... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 1.4MB)
-
- Publisher copy:
- 10.1016/s1473-3099(20)30160-2
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Infectious Diseases Journal website
- Volume:
- 20
- Issue:
- 7
- Pages:
- 816-826
- Publication date:
- 2020-04-20
- Acceptance date:
- 2020-02-28
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Pmid:
-
32325038
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1101508
- Local pid:
- pubs:1101508
- Deposit date:
- 2020-04-25
Terms of use
- Copyright holder:
- Folegatti et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record